Free shipping on all orders over $ 500


Cat. No. M2043
TAK-438 Structure

Vonoprazan Fumarate

Size Price Availability Quantity
5mg USD 220 In stock
10mg USD 300 In stock
25mg USD 600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

TAK-438 is a novel potassium-competitive acid blocker (P-CAB) type antisecretory agent that reversibly inhibits gastric H+, K+-ATPase with a K(i) of 10 nM at pH 7. TAK-438 exhibited potent H(+),K(+)-ATPase inhibitory activity and potent gastric acid secretion inhibitory action in vivo. TAK-438 increased the pH of the gastric perfusate to 5.7 in an unstimulated condition, and this effect was maintained in the presence of subsequent histamine stimulation. TAK-438 exerted a more potent and longer-lasting antisecretory effect than lansoprazole through high accumulation and slow clearance from the gastric tissue. In addition, TAK-438 was unaffected by the gastric secretory state, unlike proton pump inhibitors (PPIs).

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 461.46
Formula C17H16FN3O2S.C4H4O4
CAS Number 1260141-27-2
Purity >98%
Solubility DMSO 60 mg/mL
Storage at -20°C

A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y, et al. J Pharmacol Exp Ther. 2011 Jun;337(3):797-804. PMID: 21411494.

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.
Matsukawa J, et al. Biochem Pharmacol. 2011 May 1;81(9):1145-51. PMID: 21371447.

Related Potassium Channel Products

2,2,2-Trichloroethanol is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4).


Nigericin is an antibiotic derived from Streptomyces hygroscopicus, it acts as an H+, K+, Pb2+ ionophore.


ML213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener, with EC50 values of 230 and 510 nM for KV7.2 and KV7.4, respectively.


CLP290 is a novel, orally available KCC2 modulator, highly selective for KCC2 over related Cl- transporters.


BMS-191011 is a potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1).

Abmole Inhibitor Catalog 2017

Keywords: TAK-438, Vonoprazan Fumarate supplier, Potassium Channel, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.